InterLeukin6 IL6 Inhibitor Market Report 2025

The interleukin6 (IL6) inhibitor market size has grown strongly in recent years. It will grow from $32.57 billion in 2024 to $35.77 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing clinical trials and research, increasing awareness, increasing patient advocacy and demand, increasing public awareness and education, and increasing the emergence of biosimilars.

The interleukin6 (IL6) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $52.88 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to healthcare system infrastructure, regulatory and policy changes, funding and investment, pharmaceutical pipeline developments, and medical community endorsement. Major trends in the forecast period include advanced molecular engineering, development of novel biologics, exploration of new therapeutic areas, integration with genomic and proteomic data, and enhanced drug delivery systems.

The forecast of 10.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for COVID-19 and rheumatology care by increasing costs of tocilizumab and sarilumab imported from Japan and France, potentially reducing cytokine storm treatment options and raising critical care medication expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of neurological disorders is projected to drive the growth of the interleukin-6 (IL-6) inhibitor market in the coming years. Neurological disorders encompass a broad spectrum of conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. The increasing incidence of these disorders is attributed to factors such as an aging population, improved diagnostic techniques, heightened awareness, and lifestyle elements such as stress, sedentary behavior, and poor diet. IL-6 inhibitors play a critical role in managing neurological disorders by mitigating inflammation and reducing immune system overactivity in the brain, which can alleviate symptoms and slow disease progression in conditions such as multiple sclerosis and Alzheimer's disease. For example, a report from the National Library of Medicine in March 2023 estimated that approximately 6.7 million Americans aged 65 and older would be living with Alzheimer's dementia in 2023, a number projected to rise to 13.8 million by 2060. Consequently, the growing prevalence of neurological disorders is significantly driving the interleukin-6 inhibitor market.

Key players in the interleukin-6 (IL-6) inhibitor market are focused on developing advanced solutions, such as the first approved tocilizumab biosimilar, to broaden treatment options and enhance patient outcomes. The first approved tocilizumab biosimilar is a highly similar version of the original Actemra, which is an IL-6 receptor inhibitor used to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, a treatment for various inflammatory and immune-mediated conditions. This medication offers flexible administration options, including subcutaneous (via prefilled syringes and autoinjectors) and intravenous (via vials) formulations, allowing healthcare providers to tailor treatment to individual patient needs. Tyenne presents an accessible, affordable, high-quality, and safe alternative for European patients currently receiving tocilizumab.

In March 2022, Recordati Industria Chimica e Farmaceutica S.p.A., an Italy-based pharmaceutical company, acquired EUSA Pharma (UK) Ltd. for an undisclosed amount. This acquisition aims to broaden Recordati's portfolio in the rare disease segment, enhance its therapeutic focus on rare and niche oncology diseases, and improve its capacity to deliver innovative treatments that address significant unmet medical needs. EUSA Pharma (UK) Ltd. is a UK-based pharmaceutical company specializing in rare and oncology products, including SYLVANT (siltuximab).

Major companies operating in the interleukin6 (IL-6) inhibitor market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Sanofi S.A., Galapagos N.V., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogene Inc., Chugai Pharmaceutical Co Ltd., Celltrion Inc., Dynavax Technologies Corporation, Argenx SE, Aclaris Therapeutics Inc., Genentech Inc., Evelo Biosciences Inc., BPS Bioscience Inc., Tiziana Life Sciences PLC.

Asia-Pacific was the largest region in the interleukin6 (IL-6) inhibitor market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin6 il6 inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interleukin6 il6 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The interleukin6 (IL-6) inhibitor market consists of sales of clazakizumab, sirukumab, olokizumab, brezulimab, and mavrilimumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The interleukin6 (IL-6) inhibitor market research report is one of a series of new reports that provides interleukin6 (IL-6) inhibitor market statistics, including the interleukin6 (IL-6) inhibitor industry's global market size, regional shares, competitors with an interleukin6 (IL-6) inhibitor market share, detailed interleukin6 (IL-6) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin6 (IL-6) inhibitor industry. This interleukin6 (IL-6) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Interleukin-6 (IL-6) inhibitors are medications that block the activity of IL-6, a cytokine involved in inflammation and immune responses. These inhibitors are utilized to treat conditions such as rheumatoid arthritis, certain cancers, and other inflammatory diseases. By targeting IL-6, they help reduce inflammation and modulate the immune system.

The primary product types of IL-6 inhibitors include tocilizumab, siltuximab, and sylvan. Tocilizumab is a monoclonal antibody that blocks the IL-6 receptor and is used to treat inflammatory conditions such as rheumatoid arthritis and cytokine release syndrome. It can be administered through various routes, including intravenous (IV), subcutaneous (SC), and others. The indications for IL-6 inhibitors encompass rheumatoid arthritis, oncology, systemic juvenile idiopathic arthritis, giant cell arteritis, and COVID-19-related cytokine storm, among others. Distribution channels include retail pharmacies, hospital pharmacies, specialty pharmacies, online pharmacies, and more.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.